Prostate cancer early detection, Version 2.2016: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 5, 2016, Pages 509-519

  Carroll, Peter R ^a   Parsons, J Kellogg ^b   Andriole, Gerald ^c   Bahnson, Robert R ^d   Castle, Erik P ^e   Catalona, William J ^f   Dahl, Douglas M ^g   Davis, John W ^h   Epstein, Jonathan I ⁱ   Etzioni, Ruth B ^j   Farrington, Thomas ^k   Hemstreet, George P ^l   Kawachi, Mark H ^m   Kim, Simon ⁿ   Lange, Paul H ^o   Loughlin, Kevin R ^p   Lowrance, William ^q   Maroni, Paul ^r   Mohler, James ^s   Morgan, Todd M ^t   Moses, Kelvin A ^u   Nadler, Robert B ^f   Poch, Michael ^v   Scales, Chuck ^w   Shaneyfelt, Terrence M ^x   Smaldone, Marc C ^y   Sonn, Geoffrey ^z   Sprenkle, Preston ^aa   Vickers, Andrew J ^ab   Wake, Robert ^ac   Shead, Dorothy A ^ad   Freedman Cass, Deborah A ^ad   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e MAYO CLINIC CANCER CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j SEATTLE CANCER CARE ALLIANCE   (United States)

^k Prostate Health Education Network   (United States)

^l NEBRASKA MEDICAL CENTER   (United States)

^m Hope Comprehensive Cancer Center   (United States)

ⁿ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^o UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^p Dana Farber Brigham and Women's Cancer Center   (United States)

^q UNIVERSITY OF UTAH   (United States)

^r University of Colorado Cancer Center   (United States)

^s ROSWELL PARK CANCER INSTITUTE   (United States)

^t UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^u VANDERBILT INGRAM CANCER CENTER   (United States)

^v H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^w DUKE CANCER INSTITUTE   (United States)

^x UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^y FOX CHASE CANCER CENTER   (United States)

^z STANFORD CANCER INSTITUTE   (United States)

^aa YALE CANCER CENTER   (United States)

^ab MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ac UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^ad National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

AFRICAN AMERICAN; BIOPSY TECHNIQUE; CANCER SCREENING; EARLY CANCER DIAGNOSIS; GENE MUTATION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRACTICE GUIDELINE; PROSTATE BIOPSY; PROSTATE CANCER; RACE; REPEAT PROCEDURE; REVIEW; MALE; PROCEDURES; PROSTATIC NEOPLASMS;

EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84968764427     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0060     Document Type: Review

References (70)

1. Andriole GL. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Recent Results Cancer Res 2014; 202: 53-57.
2. Andriole GL, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-132.
3. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
4. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990.
5. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027-2035.
6. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185: 1650-1655.
7. Filella X, Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: A systematic review and meta-analysis. Clin Chem Lab Med 2013; 51: 729-739.
8. Lazzeri M, Haese A, Abrate A, et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: Results from a multicentre European study, the PROMEtheuS project. BJU Int 2013; 112: 313-321.
9. Loeb S. Prostate cancer: Prostate Health Index-improving screening in men with family history. Nat Rev Urol 2013; 10: 497-498.
10. Partin AW, Brawer MK, Subong EN, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998; 1: 197-203.
11. Bryant RJ, Sjoberg DD, Vickers AJ, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT Study. J Natl Cancer Inst 2015; 107: Pii: Djv095.
12. Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol 2015; 68: 464-470.
13. Vickers A, Cronin A, Roobol M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication. J Clin Oncol 2010; 28: 2493-2498.
14. Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011; 20: 255-261.
15. Vickers AJ. Markers for the early detection of prostate cancer: Some principles for statistical reporting and interpretation. J Clin Oncol 2014; 32: 4033-4034.
16. Wei JT, Feng Z, Partin AW, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol 2014; 32: 4066-4072.
17. Stewart GD, Van Neste L, Delvenne P, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: Results of the MATLOC study. J Urol 2013; 189: 1110-1116.
18. Partin AW, Van Neste L, Klein EA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol 2014; 192: 1081-1087.
19. Auprich M, Augustin H, Budaus L, et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int 2012; 109: 1627-1635.
20. Boegemann M, Stephan C, Cammann H, et al. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged
21. De Luca S, Passera R, Bollito E, et al. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy. Anticancer Res 2014; 34: 7159-7165.
22. De Luca S, Passera R, Fiori C, et al. Prostate health index and prostate cancer gene 3 score but not percent-free prostate specific antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy. Urol Oncol 2015; 33: 424.e417-423.
23. Ferro M, Bruzzese D, Perdona S, et al. Prostate Health Index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One 2013; 8: E67687.
24. Perdona S, Bruzzese D, Ferro M, et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013; 73: 227-235.
25. Porpiglia F, Russo F, Manfredi M, et al. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? J Urol 2014; 192: 60-66.
26. Scattoni V, Lazzeri M, Lughezzani G, et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 2013; 190: 496-501.
27. Kuru TH, Roethke MC, Seidenader J, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol 2013; 190: 1380-1386.
28. Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014; 66: 22-29.
29. Tonttila PP, Lantto J, Paakko E, et al. Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy-naive men with suspected prostate cancer based on elevated prostate-specific antigen values: Results from a randomized prospective blinded controlled trial. Eur Urol 2016; 69: 419-425..
30. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015; 313: 390-397.
31. Rastinehad AR, Turkbey B, Salami SS, et al. Improving detection of clinically significant prostate cancer: MRI/TRUS fusion-guided prostate biopsy. J Urol 2014; 191: 1749-1754.
32. Robertson NL, Emberton M, Moore CM. MRI-targeted prostate biopsy: A review of technique and results. Nat Rev Urol 2013; 10: 589-597.
33. Puech P, Rouviere O, Renard-Penna R, et al. Prostate cancer diagnosis: Multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy-prospective multicenter study. Radiology 2013; 268: 461-469.
34. Abdollah F, Novara G, Briganti A, et al. Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: Is there a difference in cancer detection rate? Urology 2011; 77: 921-925.
35. Nelson AW, Harvey RC, Parker RA, et al. Repeat prostate biopsy strategies after initial negative biopsy: Meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy. PLoS One 2013; 8: E57480.
36. Sivaraman A, Sanchez-Salas R, Barret E, et al. Transperineal template-guided mapping biopsy of the prostate. Int J Urol 2015; 22: 146-151.
37. Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: A systematic review and meta-analysis. Eur Urol 2015; 68: 438-450.
38. SEER Stat Fact Sheets: Prostate Cancer. 2015. Available at: Http: //seer.cancer. gov/statfacts/html/prost.html. Accessed April 28, 2015.
39. Bratt O. Hereditary prostate cancer: Clinical aspects. J Urol 2002; 168: 906-913.
40. Carter BS, Beaty TH, Steinberg GD, et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992; 89: 3367-3371.
41. Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 2008; 68: 1582-1591.
42. Grill S, Fallah M, Leach RJ, et al. Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator. J Urol 2015; 193: 460-465.
43. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010; 183: 1792-1796.
44. Barocas DA, Grubb R III, Black A, et al. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial. Cancer 2013; 119: 2223-2229.
45. Mahal BA, Aizer AA, Ziehr DR, et al. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology 2014; 84: 386-392.
46. Yamoah K, Johnson MH, Choeurng V, et al. Novel biomarker signature that may predict aggressive disease in african american men with prostate cancer. J Clin Oncol 2015; 33: 2789-2796.
47. Zhang H, Messing EM, Travis LB, et al. Age and racial differences among PSA-detected (AJCC stage T1cN0M0) prostate cancer in the U.S.: A population-based study of 70,345 men. Front Oncol 2013; 3: 312.
48. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
49. Robbins HA, Engels EA, Pfeiffer RM, Shiels MS. Age at cancer diagnosis for blacks compared with whites in the United States. J Natl Cancer Inst 2015; 107: Pii: Dju489.
50. Karami S, Young HA, Henson DE. Earlier age at diagnosis: Another dimension in cancer disparity? Cancer Detect Prev 2007; 31: 29-34.
51. Metcalfe C, Evans S, Ibrahim F, et al. Pathways to diagnosis for black men and white men found to have prostate cancer: The PROCESS cohort study. Br J Cancer 2008; 99: 1040-1045.
52. Vertosick EA, Poon BY, Vickers AJ. Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol 2014; 192: 724-728.
53. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91: 1310-1316.
54. Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 2009; 15: 1112-1120.
55. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-695.
56. Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-2121.
57. Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004; 10: 2918-2921.
58. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 2012; 106: 1697-1701.
59. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J Clin Oncol 2004; 22: 735-742.
60. Tulinius H, Olafsdottir GH, Sigvaldason H, et al. The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 2002; 39: 457-462.
61. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. J Med Genet 2005; 42: 711-719.
62. Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015; 121: 269-275.
63. Moran A, O'Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 2012; 11: 235-242.
64. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748-1757.
65. Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008; 98: 502-507.
66. Narod SA, Neuhausen S, Vichodez G, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008; 99: 371-374.
67. Thorne H, Willems AJ, Niedermayr E, et al. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 2011; 4: 1002-1010.
68. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 929-935.
69. Daly MB, Pilarski R, Axilbund JE, et al. NCCN Clincial Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2016. Accessed February 12, 2016. To view the most recent version of these guidelines, visit NCCN.org.
70. Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study. Eur Urol 2014; 66: 489-499.